Lakewood-Amedex Biotherapeutics
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Lakewood-Amedex Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$3.85 million of profit last year.
Lakewood-Amedex Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Lakewood-Amedex Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -9 | -4 | -4 | |
| -8 | -5 | -4 | |
| -8 | -5 | -4 | |
| -1.18 | -0.69 | -0.28 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 7 | 1 | 0 |
| Cash | 3 | 1 | 0 |
| Total debt | 1 | 0 | 2 |
| Total liabilities | 2 | 1 | 2 |
| 5 | 0 | -2 | |
| 7 | 7 | 14 | |
| -127.2% | -561.5% | – | |
| -181.7% | -1,185.4% | 195.9% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -7 | -6 | -2 | |
| – | 0 | – | |
| -7 | -6 | -2 | |
| Dividends paid | – | – | – |
| 0 | 0 | 0 | |
| 1 | 0 | 1 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Lakewood-Amedex Biotherapeutics
Is Lakewood-Amedex Biotherapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lakewood-Amedex Biotherapeutics AI analysis
What does Lakewood-Amedex Biotherapeutics do?
Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. It is in Biotechnology.
Does Lakewood-Amedex Biotherapeutics pay a dividend?
No. Lakewood-Amedex Biotherapeutics does not pay a dividend at the moment.
Is Lakewood-Amedex Biotherapeutics stock halal?
No. Lakewood-Amedex Biotherapeutics does not pass our halal screen: its debt is 177% of its market value, at or above the 33% limit. How we check
Who are Lakewood-Amedex Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Lakewood-Amedex Biotherapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.